Home > Diseases and Conditions > Hemophilia B

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M.; 2013.

A.D.A.M. Medical Encyclopedia.

Hemophilia B

Christmas disease; Factor IX hemophilia

Last reviewed: February 8, 2012.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Without enough factor IX, the blood cannot clot properly to control bleeding.

See also: Coagulation disorder

Causes, incidence, and risk factors

Hemophilia B is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome.

Females have two copies of the X chromosome. If the factor IX gene on one chromosome is defective, the gene on the other chromosome can do the job of making enough factor IX.

Males have only one X chromosome. If the factor IX gene is missing on a boy's X chromosome, he will have Hemophilia B. Most people with hemophilia B are male.

If a woman has a defective factor IX gene, she is considered a carrier. This means the defective gene can be passed down to her children. Boys born to such women have a 50% chance of having hemophilia B. Their daughters have a 50% chance of being a carrier.

All female children of men with hemophilia carry the defective gene.

Risk factors for hemophilia B include:

  • Family history of bleeding
  • Being male

Symptoms

The severity of symptoms can vary, and the severe forms become apparent early on.

Bleeding is the main symptom. It is often first seen when the an infant is circumcised. Additional bleeding problems usually show up when the infant starts crawling and walking.

Mild cases may go unnoticed until later in life. Symptoms may first occur after surgery or injury. ur in response to surgery. Internal bleeding may occur anywhere.

Symptoms can include:

  • Bleeding into joints and associated pain and swelling
  • Excessive bleeding following circumcision
  • Gastrointestinal tract and urinary tract hemorrhage
  • Prolonged bleeding from cuts, tooth extraction, and surgery
  • Spontaneous bleeding

Signs and tests

If you are the first person in the family to have a suspected bleeding disorder, your doctor will order a series of tests called a coagulation study. Once the specific defect has been identified, other people in your family will need tests to diagnose the disorder.

Blood tests results may include:

Treatment

Treatment includes replacing the defective clotting factor. You will receive factor IX concentrates. How much you get depends on:

  • Severity of bleeding
  • Site of bleeding
  • Your weight and height

To prevent a bleeding crisis, people with hemophilia and their families can be taught to administer factor IX concentrates at home at the first signs of bleeding. People with severe forms of the disease may need ongoing, preventive infusions.

If you have severe hemophilia, you may also need to take factor IX concentrate before surgery or certain types of dental work.

You should get the Hepatitis B vaccine. People with hemophilia are more likely to get hepatitis because they may receive blood products.

Expectations (prognosis)

With treatment, most people with hemophilia are able to lead relatively normal lives. However, death from extreme blood loss can occur.

If you have hemophilia, you should have regular check ups with a hematologist.

Complications

Complications can include :

  • Long-term joint problems, which may require a joint replacement
  • Bleeding in the brain (intracerebral hemorrhage)
  • Thrombosis due to treatment

Repeated transfusions may slightly raise the risk for HIV and hepatitis. However, continued improvements in blood screening procedures makes blood products safer than ever.

Calling your health care provider

Call your health care provider if:

  • Symptoms of a bleeding disorder develop
  • A family member has been diagnosed with hemophilia B
  • If you have hemophilia B, and you plan to have children; genetic counseling is available

Prevention

Genetic counseling may be recommended. Testing can identify women and girls who carry the hemophilia gene.

Testing can be done during pregancy on a baby that is in the mother's womb.

References

  1. Ragni MV. Hemorrhagic disorders: coagulation factor deficiencies. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 167.

Review Date: 2/8/2012.

Reviewed by: Todd Gersten, MD, Hematology/Oncology, Palm Beach Cancer Institute, West Palm Beach, FL. Review provided by VeriMed Healthcare Network; Linda J. Vorvick, MD, Medical Director and Director of Didactic Curriculum, MEDEX Northwest Division of Physician Assistant Studies, Department of Family Medicine, UW Medicine, School of Medicine, University of Washington. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

Copyright © 2013, A.D.A.M., Inc.

What works?

  • Recombinant factor VIIa clotting factor concentrates (containing no human proteins) compared to concentrates derived from plasma to treat acute bleeds in haemophiliacs with inhibitorsRecombinant factor VIIa clotting factor concentrates (containing no human proteins) compared to concentrates derived from plasma to treat acute bleeds in haemophiliacs with inhibitors
    Haemophilia is an inherited bleeding disorder caused by a deficiency of a clotting factor and is characterised by bleeding into the joints. It is treated by the injecting a drug containing the missing clotting factor into veins. In some individuals with haemophilia, this factor is seen by the body as a foreign protein when it is injected and the body produces an antibody (inhibitor) that destroys the factor. In this way these people become resistant to treatment. Once someone with haemophilia develops an inhibitor, they are treated to eradicate the antibody (immunotolerance induction) and for acute bleeding episodes. Treatment for bleeding episodes is with one of two available bypassing agents, recombinant activated factor VIIa (Novoseven) or human activated prothrombin complex concentrate (FEIBA). It is not known if one of these products is better than the other. We searched for trials comparing the effectiveness (time until bleeding stops, effect on joint motion, need for re‐treatment) and safety of Novoseven and FEIBA in people with haemophilia with inhibitors during episodes of acute bleeding. We found two clinical trials comparing Novoseven and FEIBA. The trials did not show a difference in the effectiveness of the two products and both were equally safe in terms of tolerability and the absence of clotting complications. We conclude that both recombinant factor VIIa and plasma derived concentrates can be used to treat bleeds in individuals with haemophilia and inhibitors.
See all (2) ...

Figures

  • X-linked recessive genetic defects - how boys are affected.
    X-linked recessive genetic defects - how girls are affected.
    X-linked recessive genetic defects.
    Blood cells.
    Blood clots.

Learn about...

  • How we know if a treatment worksHow we know if a treatment works
    Testing Treatments is a lively look at modern clinical research, and how everyone can get involved in using and improving research for better health care.

MedlinePlus.gov links to free, reliable, up-to-date health information from the National Institutes of Health (NIH) and other trusted health organizations.

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk